S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:TYME

Tyme Technologies Stock Forecast, Price & News

$1.80
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.58
Now: $1.80
$1.84
50-Day Range
$1.72
MA: $2.23
$3.53
52-Week Range
$0.85
Now: $1.80
$4.99
Volume4.28 million shs
Average Volume15.10 million shs
Market Capitalization$234.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Tyme Technologies logo

Headlines

Why Tyme Technologies Stock Is Taking Off Today
February 9, 2021 |  finance.yahoo.com
Why Tyme Stock Got Demolished Today
February 4, 2021 |  finance.yahoo.com
Why Tyme Technologies Stock Is Crushing It Today
February 3, 2021 |  finance.yahoo.com
Stock Alert: Tyme Technologies Soars 150%
February 3, 2021 |  nasdaq.com
Time to Wear Your Vitamins?
January 7, 2021 |  msn.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315
Employees18
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-22,000,000.00

Miscellaneous

Market Cap$234.77 million
Next Earnings Date5/19/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

769th out of 1,972 stocks

Pharmaceutical Preparations Industry

366th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.80
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

Is Tyme Technologies a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tyme Technologies stock.
View analyst ratings for Tyme Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Tyme Technologies?

Wall Street analysts have given Tyme Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 4,100,000 shares, an increase of 65.3% from the January 28th total of 2,480,000 shares. Based on an average daily volume of 9,810,000 shares, the short-interest ratio is currently 0.4 days. Currently, 4.9% of the shares of the stock are short sold.
View Tyme Technologies' Short Interest
.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for Tyme Technologies
.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) issued its earnings results on Thursday, February, 4th. The company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.02.
View Tyme Technologies' earnings history
.

How has Tyme Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TYME stock has increased by 71.4% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TYME?

2 equities research analysts have issued twelve-month price objectives for Tyme Technologies' stock. Their forecasts range from $9.50 to $9.50. On average, they anticipate Tyme Technologies' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 427.8% from the stock's current price.
View analysts' price targets for Tyme Technologies
or view top-rated stocks among Wall Street analysts.

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman & Chief Science Officer (Age 58, Pay $900.79k)
  • Mr. Richard Cunningham, CEO & Director (Age 50)
  • Ms. Barbara C. Galaini, Acting Principal Financial Officer, Principal Accounting Officer & Corp. Controller (Age 63)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 57)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 59)
  • Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 47)
  • Mr. John Zucaro P.E., Sr. VP of CMC
  • Dr. John M. Rothman, Exec. VP of Product Devel. (Age 73)

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.42%), Northern Trust Corp (0.56%), Nuveen Asset Management LLC (0.29%), Bank of New York Mellon Corp (0.18%), JPMorgan Chase & Co. (0.14%) and Wells Fargo & Company MN (0.09%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman.
View institutional ownership trends for Tyme Technologies
.

Which institutional investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Northern Trust Corp, Barclays PLC, and Bank of New York Mellon Corp. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
or view top insider-selling stocks.

Which institutional investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Nuveen Asset Management LLC, and Rhumbline Advisers. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michele Ilene Korfin, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
or or view top insider-buying stocks.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.80.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $234.77 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

Where are Tyme Technologies' headquarters?

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.